28 January 2022 - The government granted health insurance benefits for Bausch Health Korea’s glaucoma treatment Vyzulta (latanoprostene bunod) and Kolon Pharma’s psoriasis treatment Skilarence (dimethyl fumarate) from February.

Also, the government expanded the reimbursement scope for Pfizer’s Besponsa (inotuzumab ozogamicin), treatment for acute lymphoblastic leukaemia. The benefit will cover not only Philadelphia chromosome negative acute lymphoblastic leukaemia remission induction therapy but Philadelphia chromosome positive acute lymphoblastic leukaemia remission induction and positive/negative acute lymphoblastic leukaemia remission consolidation therapy.

Read Korea Biomedical Review article